Scilex Holding Company
Scilex Holding Company
- Market cap
- $14.07M
Your view on SCLXW
Overview
What the company does, where it operates, and who runs it.
About Scilex Holding Company
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Henry H. Ji
- Headquarters
- 960 San Antonio Road, Palo Alto, CA, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Henry H. Ji
- Headquarters
- 960 San Antonio Road, Palo Alto, CA, US
Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.
8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection.
The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain.
Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia.
Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Scilex Holding Company. Starting points for Scilex Holding Company: EPS -$64.87, beta 1.74 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Scilex Holding Company. Trailing twelve-month EPS for Scilex Holding Company stands at -$64.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Scilex Holding Company. Scilex Holding Company has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| GIFOFGrifols, S.A. | Healthcare | OTC | $8.7B | ||
| GIKLYGrifols, S.A. | Healthcare | OTC | $17.0B | ||
| GILDGilead Sciences, Inc. | Healthcare | NASDAQ | $206.4B | ||
| GLAXFGSK plc | Healthcare | OTC | $118.6B | ||
| GRFSGrifols, S.A. | Healthcare | NASDAQ | $6.9B | ||
| GSKGSK plc | Healthcare | NYSE | $96.3B | ||
| HAWPFHaw Par Corporation Limited | Healthcare | OTC | $3.1B | ||
| HAWPYHaw Par Corporation Limited | Healthcare | OTC | $3.0B | ||
| JCRRFJCR Pharmaceuticals Co., Ltd. | Healthcare | OTC | $508.7M | ||
| JNJJohnson & Johnson | Healthcare | NYSE | $651.1B | ||
| LLYEli Lilly and Company | Healthcare | NYSE | $1.3T | ||
| LLY.TOEli Lilly and Company | Healthcare | TSX | $1.7T | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Scilex Holding Company executives and directors. Shares of Scilex Holding Company have traded between $0.17 and $0.21 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Scilex Holding Company. Coverage tracks Scilex Holding Company within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Scilex Holding Company.